HARP(Delisted)
Harpoon TherapeuticsยทNASDAQ
--
--(--)
HARP Profile
Harpoon Therapeutics, Inc.
A clinical-stage immunotherapy company that developing a novel class of T cell to treat cancer and other diseases
131 Oyster Point Blvd, Suite 300 , South San Francisco, CA 94080
--
Harpoon Therapeutics, Inc., was incorporated in Delaware in March 2015. They are a clinical-stage immunotherapy company developing a new type of T-cell participant that harnesses the power of the human immune system to treat patients with cancer and other diseases. Using their proprietary Tri-specific T cell activation constructs, or TriTAC platform, they are developing a pipeline of new T cell participants, or TriTACs, initially focused on the treatment of solid tumors and hematological malignancies. Since starting operations in 2015, they have created four TriTAC product candidates, and they expect to have four TriTACs for clinical development by the end of 2020.
